Skip to main content
    O

    Oric Pharmaceuticals Inc (ORIC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.52
    -0.34 (-4.33%)

    Market Cap: $814.71M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Oric Pharmaceuticals Inc (ORIC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 16, 2026. Financial statements from company filings, amounts in US dollars.

    Oric Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$129.47M, operating cash flow was -$110.97M and free cash flow was -$111.68M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$48.08M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $143.00M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Cost of revenue$0$0$0$0$0$0$0$0$900.00K
    Gross profit$0$0$0$0$0$0$0$0-$900.00K
    Research and development$109.82M$114.07M$85.17M$66.68M$56.86M$60.76M$22.84M$19.03M$19.13M
    Operating income-$143.00M-$142.90M-$110.78M-$91.77M-$78.87M-$74.19M-$28.57M-$22.37M-$22.54M
    Net income-$129.47M-$127.85M-$100.70M-$89.12M-$78.72M-$73.70M-$26.88M-$21.36M-$22.03M
    EBITDAN/AN/AN/AN/A-$76.61M-$72.74M-$27.25M-$21.23M-$21.13M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.07M$0$0$0$1.54M
    Gross profit$0$0$0-$320.00K$0$0$0-$304.00K$0$0$0-$263.00K
    Operating income-$51.55M-$45.30M-$39.62M-$34.55M-$36.67M-$39.06M-$32.72M-$39.57M-$38.32M-$36.02M-$28.99M-$31.43M
    Net income-$48.08M-$41.49M-$35.77M-$30.50M-$32.59M-$36.35M-$30.02M-$36.31M-$34.57M-$31.96M-$25.01M-$28.33M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $3.33M by $42.34M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$408.89M$274.14M$252.01M$247.18M$298.64M$299.00M$94.09M$46.73M$30.02M
    Current assets$288.47M$262.25M$212.60M$210.46M$240.52M$296.70M$90.00M$43.72M$26.61M
    Cash and equivalents$45.67M$59.41M$23.38M$66.84M$226.01M$78.45M$89.16M$42.64M$25.82M
    Total liabilities$24.53M$31.02M$27.92M$24.83M$25.67M$9.22M$6.12M$111.16M$4.30M
    Short-term debt$3.33M$3.18M$2.75M$2.66M$1.93M$546.00K$495.00KN/AN/A
    Shareholder equity$384.36M$243.12M$224.09M$222.35M$272.98M$289.78M-$90.08M-$64.43M$25.73M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$366.89M$404.69M$436.76M$411.00M$431.19M$346.86M$242.86M$274.14M$302.07M$328.91M$350.79M$254.69M
    Total liabilities$27.38M$23.43M$21.20M$26.64M$24.27M$22.86M$23.12M$31.02M$28.08M$26.51M$22.14M$30.60M
    Cash and equivalents$33.85M$37.48M$56.40M$45.67M$49.67M$75.86M$49.33M$59.41M$44.23M$49.83M$56.36M$23.38M
    Shareholder equity$339.50M$381.26M$415.56M$384.36M$406.92M$324.00M$219.74M$243.12M$273.99M$302.40M$328.64M$224.09M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$110.97M-$112.66M-$85.69M-$75.14M-$59.54M-$45.27M-$23.53M-$20.68M-$20.83M
    Capital expenditures$712.00K$1.19M$849.00K$2.08M$939.00K$667.00K$768.00K$525.00K$486.00K
    Free cash flow-$111.68M-$113.85M-$86.54M-$77.22M-$60.48M-$45.94M-$24.30M-$21.21M-$21.32M
    Share repurchases$2.40M$168.00KN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$148.03M$22.14M-$43.40M-$109.25M$158.44M-$215.96M-$768.00K-$508.00K-$292.00K
    Financing cash flow$245.26M$126.55M$85.66M$25.23M$49.13M$250.51M$70.82M$38.01M$260.00K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$41.99M-$31.61M-$32.44M-$22.48M-$25.11M-$30.84M-$32.53M-$28.05M-$28.80M-$25.63M-$30.19M-$24.27M
    Capital expenditures$107.00K$356.00K$2.00K$227.00K$35.00K$63.00K$387.00K$219.00K$418.00K$333.00K$218.00K$57.00K
    Free cash flow-$42.09M-$31.96M-$32.44M-$22.71M-$25.15M-$30.91M-$32.92M-$28.27M-$29.21M-$25.96M-$30.40M-$24.33M
    Last 12 quarters

    Frequently Asked Questions About ORIC

    What is Oric Pharmaceuticals' annual revenue?

    Oric Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Oric Pharmaceuticals profitable?

    No. Oric Pharmaceuticals reported net income of -$129.47M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ORIC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$110.97M minus capital expenditures of $712.00K produced free cash flow of -$111.68M.

    How much debt does Oric Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.33M and cash and equivalents of $45.67M.